Clinical trials: Recurrent Oral Cavity Squamous Cell Carcinoma
Head and Neck Neoplasms
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.
- Trial name
- NCT00768664
- Testing
- PF-00299804
- Where
- 10 sites in Canada
- Volunteers
- 69 people
- Sponsor
- Pfizer
Head and Neck Cancer
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or…
- Trial name
- NCT00006471
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
This phase I trial studies the side effects and the best dose of lenalidomide when given together with cetuximab in treating patients with colorectal cancer or head and neck cancer that has spread to other places in the body and…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- ADCC (NCT01254617)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Head and Neck Cancer
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical research study is to learn if the addition of OSI-906 to cetuximab can improve response. The safety of these drugs will also be studied.
- Trial name
- NCT01427205
- Testing
- Cetuximab, OSI-906
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002507
- Testing
- mitomycin C, porfiromycin, brachytherapy
- Where
- United States
- Sponsor
- Yale University
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00470496
- Testing
- HPPH, photodynamic therapy, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Oral Complications
Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy at different times of the day may affect the chance of developing side effects such as mucositis.
- Trial name
- NCT00004234
- Testing
- management of therapy complications, radiation therapy
- Where
- 14 sites in Canada
- Sponsor
- NCIC Clinical Trials Group
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01528137
- Testing
- talactoferrin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Head and Neck Cancer
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030576
- Testing
- cisplatin, erlotinib hydrochloride
- Where
- 6 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This partially randomized phase II trial studies giving capecitabine and vorinostat in treating patients with head and neck cancer that has come back after previous treatment or that has spread to other areas in the body.
- Conditions
- Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT01267240
- Testing
- Capecitabine, Vorinostat
- Where
- 14 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00629226
- Testing
- cetuximab, bortezomib, cisplatin
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity
CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC
This is a prospective single-arm loading test study of CHG0521 oral coating in patients with solid tissue tumor/recurrent/metastatic TSCC
- Trial name
- NCT06609070
- Testing
- CHG0521 Oral Coating
- Volunteers
- 30 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Head and Neck Cancer
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
RATIONALE: Diagnostic procedures, such as specialized types of magnetic resonance imaging (MRI), may help in planning radiation therapy that does less damage to normal tissues.
- Trial name
- NCT00984074
- Testing
- blood-oxygen-level-dependent functional magnetic resonance imaging, diffusion tensor imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
This is a phase 1b study in adult patients diagnosed with resistant or recurrent head and neck squamous cell carcinoma (HNSCC) designed to assess the safety and tolerability of IK-175 in combination with nivolumab.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer, Neck Cancer
- Trial name
- NCT05472506
- Testing
- IK-175 + nivolumab
- Where
- 4 sites in United States
- Sponsor
- Ikena Oncology
Head and Neck Cancer
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to…
- Trial name
- NCT00004070
- Testing
- IL-12
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
This phase I/II trial is studying the side effects of erlotinib and to see how well it works in treating patients with metastatic or unresectable non-small cell lung cancer, ovarian cancer, or squamous cell carcinoma (cancer) of…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00063895
- Testing
- erlotinib hydrochloride, pharmacological study, pharmacogenomic studies
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)